JP2018529747A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529747A5
JP2018529747A5 JP2018517617A JP2018517617A JP2018529747A5 JP 2018529747 A5 JP2018529747 A5 JP 2018529747A5 JP 2018517617 A JP2018517617 A JP 2018517617A JP 2018517617 A JP2018517617 A JP 2018517617A JP 2018529747 A5 JP2018529747 A5 JP 2018529747A5
Authority
JP
Japan
Prior art keywords
antibody
medicament
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018517617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529747A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/055841 external-priority patent/WO2017062682A2/en
Publication of JP2018529747A publication Critical patent/JP2018529747A/ja
Publication of JP2018529747A5 publication Critical patent/JP2018529747A5/ja
Priority to JP2021090543A priority Critical patent/JP2021152026A/ja
Priority to JP2023093742A priority patent/JP2023123521A/ja
Priority to JP2025134905A priority patent/JP2025170299A/ja
Pending legal-status Critical Current

Links

JP2018517617A 2015-10-06 2016-10-06 多発性硬化症を治療するための方法 Pending JP2018529747A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021090543A JP2021152026A (ja) 2015-10-06 2021-05-28 多発性硬化症を治療するための方法
JP2023093742A JP2023123521A (ja) 2015-10-06 2023-06-07 多発性硬化症を治療するための方法
JP2025134905A JP2025170299A (ja) 2015-10-06 2025-08-13 多発性硬化症を治療するための方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201562238103P 2015-10-06 2015-10-06
US62/238,103 2015-10-06
US201562238674P 2015-10-07 2015-10-07
US62/238,674 2015-10-07
US201562271985P 2015-12-28 2015-12-28
US62/271,985 2015-12-28
US201662296049P 2016-02-16 2016-02-16
US62/296,049 2016-02-16
US201662322734P 2016-04-14 2016-04-14
US62/322,734 2016-04-14
US201662342633P 2016-05-27 2016-05-27
US62/342,633 2016-05-27
US201662355299P 2016-06-27 2016-06-27
US62/355,299 2016-06-27
PCT/US2016/055841 WO2017062682A2 (en) 2015-10-06 2016-10-06 Method for treating multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021090543A Division JP2021152026A (ja) 2015-10-06 2021-05-28 多発性硬化症を治療するための方法

Publications (2)

Publication Number Publication Date
JP2018529747A JP2018529747A (ja) 2018-10-11
JP2018529747A5 true JP2018529747A5 (enExample) 2019-11-14

Family

ID=57223757

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018517617A Pending JP2018529747A (ja) 2015-10-06 2016-10-06 多発性硬化症を治療するための方法
JP2021090543A Withdrawn JP2021152026A (ja) 2015-10-06 2021-05-28 多発性硬化症を治療するための方法
JP2023093742A Pending JP2023123521A (ja) 2015-10-06 2023-06-07 多発性硬化症を治療するための方法
JP2025134905A Pending JP2025170299A (ja) 2015-10-06 2025-08-13 多発性硬化症を治療するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021090543A Withdrawn JP2021152026A (ja) 2015-10-06 2021-05-28 多発性硬化症を治療するための方法
JP2023093742A Pending JP2023123521A (ja) 2015-10-06 2023-06-07 多発性硬化症を治療するための方法
JP2025134905A Pending JP2025170299A (ja) 2015-10-06 2025-08-13 多発性硬化症を治療するための方法

Country Status (18)

Country Link
US (3) US20180327505A1 (enExample)
EP (2) EP3359572B1 (enExample)
JP (4) JP2018529747A (enExample)
KR (2) KR20180075537A (enExample)
CN (1) CN108431038A (enExample)
DK (1) DK3359572T3 (enExample)
ES (1) ES3007182T3 (enExample)
FI (1) FI3359572T3 (enExample)
HK (1) HK1257072A1 (enExample)
HR (1) HRP20250052T1 (enExample)
HU (1) HUE069935T2 (enExample)
IL (3) IL293708B1 (enExample)
LT (1) LT3359572T (enExample)
PL (1) PL3359572T3 (enExample)
PT (1) PT3359572T (enExample)
RS (1) RS66408B1 (enExample)
SI (1) SI3359572T1 (enExample)
WO (1) WO2017062682A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114375306A (zh) * 2019-09-11 2022-04-19 诺华股份有限公司 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
TWI899163B (zh) * 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
JP2023537751A (ja) * 2020-08-14 2023-09-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト オクレリズマブで多発性硬化症を治療するための方法
CN121358505A (zh) 2023-07-28 2026-01-16 株式会社实瞳 抗棘阿米巴用液剂

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DE69031919T3 (de) 1989-07-19 2005-01-27 Connetics Corp., Palo Alto T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン コーポレーション Hiv感染治療のための異種複合抗体
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス,インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69322860T2 (de) 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
AU4721901A (en) 2000-02-25 2001-09-03 Immunex Corp Integrin antagonists
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
EP1286692A4 (en) 2000-04-25 2004-11-17 Idec Pharma Corp INTRATHECAL ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF LYMPHOMAS OF THE CENTRAL NERVOUS SYSTEM
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
CN1325480C (zh) 2000-08-18 2007-07-11 味之素株式会社 苯基丙氨酸衍生物
AU2001290303A1 (en) 2000-09-29 2002-04-15 Ajinomoto Co., Inc. Novel phenylalanine derivatives
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
WO2003010135A1 (en) 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Novel phenylpropionic acid derivatives
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
JPWO2003089410A1 (ja) 2002-04-19 2005-08-25 協和醗酵工業株式会社 フェニルアラニン誘導体
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
JP2014506258A (ja) * 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用
EP2530088A1 (en) * 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis

Similar Documents

Publication Publication Date Title
CA2856646C (en) Combination treatment of cancer
Faissner et al. Oral therapies for multiple sclerosis
JP2015526458A5 (enExample)
JP5646617B2 (ja) 多発性硬化症の治療のための組成物および方法
CN108884053B (zh) 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法
JPH11507951A (ja) セレジリン投与による末梢ニューロパシーの予防および治療方法
JP2019517542A5 (enExample)
JP2020534362A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2016516016A5 (enExample)
JP2020534270A5 (enExample)
JP2020521797A5 (enExample)
JP2018507243A5 (enExample)
JP2018529747A5 (enExample)
JP2020535149A5 (enExample)
JP2016510343A5 (enExample)
JP2017533220A5 (enExample)
JP2017503014A5 (enExample)
JP2019508476A5 (enExample)
JP2015172060A5 (enExample)
JP2018526345A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
JP2016512247A5 (enExample)
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
JP2009538935A5 (enExample)
JP2015512923A5 (enExample)
WO2016020944A1 (en) Use in single pill/tablet/capsule of minocycline, fluconazole and atorvastatin in the treatment of multiple sclerosis